Skip to main content
Terug
Watch Compare

Metagenomi Therapeutics, Inc.

Datakwaliteit: 100%
MGX
Nasdaq Manufacturing Chemicals
€ 1,38
▼ € 0,01 (-0,72%)
Marktkapitalisatie: 51,73 M
Prijs
€ 1,38
Marktkapitalisatie
51,73 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -89,47 M
Capital efficient — spends only 2,28% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-51,79%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-46,95%
Boven sectorgemiddelde (-53,34%)
ROIC-33,17%
Net Margin-348,54%
Op. Margin-380,85%

Veiligheid

Debt / Equity
N/A
Current Ratio6,42
Interest CoverageN/A

Waardering

PE (TTM)
-0,59
Boven sectorgemiddelde (-1,47)
P/B Ratio0,29
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,6 -1,5
P/B 0,3 1,6
ROE % -47,0 -53,3
Net Margin % -348,5 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

3 analisten
Buy
Huidig
€ 1,38
+576.3%
Koersdoel
€ 9,33
€ 7,00
€ 9,00
€ 12,00
Vooruitzicht
Forward K/W -0,83
Forward WPA -€ 1,67
Omzet Sch. 21,50 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 1,67
-€ 3,04 – -€ 0,91
 21,50 M 4
FY2026 -€ 2,17
-€ 2,29 – -€ 2,03
 22,22 M 3

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,59 -€ 0,60 -2,6%
Q32025 -€ 0,53 -€ 0,55 -3,1%
Q22025 -€ 0,61 -€ 0,54 +12,0%
Q12025 -€ 0,51 -€ 0,68 -33,3%

ETFs Holding This Stock

BRUSX BRUSX
0,59% weight
BRSIX BRSIX
0,13% weight
AVDS logo AVDS Avantis International Small Cap Equity ETF
0,00% weight
AVDVX AVDVX
0,00% weight
AVANX AVANX
0,00% weight
AVDNX AVDNX
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -51,79% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 25,21 M Net Income (TTM) -87,87 M
ROE -46,95% ROA -33,78%
Gross Margin N/A Operating Margin -380,85%
Net Margin -348,54% Free Cash Flow (TTM) -89,47 M
ROIC -33,17% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 6,42
Interest Coverage N/A Asset Turnover 0,10
Working Capital 160,24 M Tangible Book Value 178,45 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,59 Forward P/E N/A
P/B Ratio 0,29 P/S Ratio 2,05
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -172,95%
Market Cap 51,73 M Enterprise Value 18,96 M
Per Share
EPS (Diluted TTM) -2,36 Revenue / Share 0,67
FCF / Share -2,38 OCF / Share -2,36
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2,28% FCF Conversion 101,82%
SBC-Adj. FCF -103,68 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 25,21 M 52,30 M
Net Income -87,87 M -78,06 M
EPS (Diluted) -2,36 -2,36
Gross Profit — —
Operating Income -96,01 M -88,90 M
EBITDA — —
R&D Expenses 94,43 M 109,18 M
SG&A Expenses — —
D&A — —
Interest Expense — —
Income Tax -58.000,0 -5,51 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 221,10 M 324,60 M
Total Liabilities 62,51 M 89,74 M
Shareholders' Equity 158,60 M 234,86 M
Total Debt — —
Cash & Equivalents 41,72 M 27,39 M
Current Assets 165,54 M 257,96 M
Current Liabilities 22,93 M 37,31 M